Tiempo real estimado
Otros sitios de cotización
|
||
93,04 CHF | 0,00 % |
|
14/06 | El regulador de la UE obliga a actualizar las etiquetas de las terapias CAR-T contra el cáncer | RE |
14/06 | Bolsa de Madrid: Los ganadores se lo llevan todo | ![]() |
Resumen de negocios
- oncología (29,9%);
- inmunología (17,2%)
- enfermedades cardiovasculares, renales y metabólicas (14,1%)
- neurociencia (8,9%).
El resto de las ventas netas (29,9%) procede de la fabricación por contrato de productos farmacéuticos.
A finales de 2023, Novartis AG contaba con 33 centros de producción en todo el mundo.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Europa (33%), Estados Unidos (39,5%), Asia/África/Australasia (20,5%), Canadá y Latinoamérica (7%).
Ventas por actividad
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Ventas por región
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4,28 % |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26,41 % |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25,63 % |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25,94 % |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1,73 % |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23,04 % |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17,90 % |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27,09 % |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26,88 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 48 | 01/01/05 | |
Director of Finance/CFO | 59 | 01/01/03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16/05/22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01/04/17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01/12/18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01/01/04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01/08/13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01/05/22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01/09/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01/01/13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28/02/20 |
Chairman | 68 | 01/01/13 | |
John Young
BRD | Director/Board Member | 60 | 07/03/23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 28/02/20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01/01/16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01/01/13 |
Nancy Andrews
BRD | Director/Board Member | 65 | 01/01/15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28/02/19 |
Frans van Houten
BRD | Director/Board Member | 64 | 28/02/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 2 189 930 497 | 1 866 336 959 ( 85,22 %) | 233 443 766 ( 10,66 %) | 85,22 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
NOVARTIS AG 6.63% | 145 083 991 | 6.63% | 14 983 623 163 $ |
MORPHOSYS AG 51.00% | 19 235 376 | 51.00% | 1 433 544 095 $ |
SANDOZ GROUP AG 2.99% | 12 886 900 | 2.99% | 457 966 018 $ |
NOVARTIS INDIA LIMITED 70.68% | 17 450 680 | 70.68% | 218 239 949 $ |
THIRD HARMONIC BIO, INC. 6.45% | 2 642 762 | 6.45% | 35 175 162 $ |
ERASCA, INC. 4.74% | 12 307 692 | 4.74% | 31 015 384 $ |
OCULIS HOLDING AG 4.66% | 1 713 521 | 4.66% | 20 151 007 $ |
MOLECULAR PARTNERS AG 4.74% | 1 739 130 | 4.74% | 6 554 381 $ |
413 581 | 5.97% | 5 335 195 $ |
Información de la empresa
![Dirección Novartis AG](https://cdn.zonebourse.com/static/address/408414.png)
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Novartis Healthcare Pvt Ltd.
![]() Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
| |
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma GmbH
![]() Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. |
Pharmaceuticals: Major
|
Sandoz GmbH
![]() Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Alcon Ophthalmika GmbH
| |
EBEWE Pharma Ges.m.b.H. Nfg.KG
![]() EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Varia. 1 de ene. | Capi. | |
---|---|---|
+52,44 % | 797 mil M | |
+40,55 % | 628 mil M | |
-7,29 % | 351 mil M | |
+17,24 % | 323 mil M | |
+10,62 % | 300 mil M | |
+17,13 % | 244 mil M | |
+1,39 % | 223 mil M | |
+6,18 % | 163 mil M | |
-5,23 % | 153 mil M |
- Bolsa de valores
- Acciones
- Acción NOVN
- Acción
- Empresa Novartis AG